Targeting mTOR Signaling Can Prevent the Progression of FSGS
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Mammalian target of rapamycin (mTOR) signaling is involved in a variety of kidney diseases. Clinical trials administering mTOR inhibitors to patients with FSGS, a prototypic podocyte disease, led to conflicting results, ranging from remission to deterioration of kidney function. Here, we combined complex genetic titration of mTOR complex 1 (mTORC1) levels in murine glomerular disease models, pharmacologic studies, and human studies to precisely delineate the role of mTOR in FSGS. mTORC1 target genes were significantly induced in microdissected glomeruli from both patients with FSGS and a murine FSGS model. Furthermore, a mouse model with constitutive mTORC1 activation closely recapitulated human FSGS. Notably, the complete knockout of mTORC1 by induced deletion of both Raptor alleles accelerated the progression of murine FSGS models. However, lowering mTORC1 signaling by deleting just one Raptor allele ameliorated the progression of glomerulosclerosis. Similarly, low-dose treatment with the mTORC1 inhibitor rapamycin efficiently diminished disease progression. Mechanistically, complete pharmacologic inhibition of mTOR in immortalized podocytes shifted the cellular energy metabolism toward reduced rates of oxidative phosphorylation and anaerobic glycolysis, which correlated with increased production of reactive oxygen species. Together, these data suggest that podocyte injury and loss is commonly followed by adaptive mTOR activation. Prolonged mTOR activation, however, results in a metabolic podocyte reprogramming leading to increased cellular stress and dedifferentiation, thus offering a treatment rationale for incomplete mTOR inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The mechanisms underlying the activation of autophagy in FSGS podocytes remain largely unclear, but activation of mTORC1 (REFS166,170) and downregulation of SIRPα138 were observed in glomeruli from both patients with FSGS and in mouse models of FSGS.”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J., Balkrishnan, R., Bragg-Gresham, J., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,191
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
A principle for counting tissue structures on random sections
Weibel, E. R., & Gomez, D. M. (1962) · Journal of Applied Physiology · doi:10.1152/jappl.1962.17.2.343 · Cited by 833
Focal Segmental Glomerulosclerosis
D'Agati, V. D., Kaskel, F. J., & Falk, R. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1106556 · Cited by 825
Cited by
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Self-citationAutophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
The hallmarks of mitochondrial dysfunction in chronic kidney disease
Galvan, D. L., Green, N. H., & Danesh, F. R. (2017) · Kidney International · doi:10.1016/j.kint.2017.05.034 · Cited by 447
“Despite all these differences, there are some hallmark features of mitochondrial dysfunction that are commonly described in the context of CKD which include, changes in mitochondrial morphology and mitochondrial remodeling, enhanced mitochondrial oxidative stress, and a significant decrease in mitochondrial biogenesis…”
BackgroundBrinkkoetter, P. T., Bork, T., Salou, S., Liang, W., Mizi, A., Özel, C., Koehler, S., Hagmann, H. H., Ising, C., Kuczkowski, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.012 · Cited by 175
“Similarly, a transgenic mouse model with genetic activation of mTOR resulted in increased metabolic signaling and the onset of FSGS (Zschiedrich et al., 2017).”
BackgroundSelf-citationOxidative Stress and Renal Fibrosis: Mechanisms and Therapies
Su, H., Wan, C., Song, A., Qiu, Y., Xiong, W., & Zhang, C. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8871-2_29 · Cited by 164
Metadata
- Authors
- Zschiedrich, S., Bork, T., Liang, W., Wanner, N., Eulenbruch, K., Munder, S., Hartleben, B., Kretz, O., Gerber, S., Simons, M., Viau, A., Burtin, M., Wei, C., Reiser, J., Herbach, N., Rastaldi, M.-P., Cohen, C. D., Tharaux, P.-L., Terzi, F., Walz, G., Gödel, M., & Huber, T. B.
- Affiliations
- University of Freiburg (DE)
- Inserm (FR)
- Rush University Medical Center (US)
- Ludwig-Maximilians-Universität München (DE)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- München Klinik (DE)
- Corresponding author
- Zschiedrich, Stefan
- Bork, Tillmann
- Liang, Wei
- Wanner, Nicola
- Eulenbruch, Kristina
- Munder, Stefan
- Hartleben, Björn
- Kretz, Oliver
- Viau, Amandine
- Herbach, Nadja
- Walz, Gerd
- Gödel, Markus
- Huber, Tobias B
- ORCID
- Venue
- Journal of the American Society of Nephrology
- Published
- 2017-03-07
- Volume
- 28
- Issue
- 7
- Pages
- 2144-2157
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC5491276
- OpenAlex
- W2594291574
- Cited by
- 76
- References
- 55
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 10 · 2019: 7 · 2018: 6 · 2017: 6
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (HU 1016/8‐1, CRC1140, 1016/8-1, 616891, GSC‐4, GSC-4/Spemann Graduate School, (EXC 294), CRC992)
- Bundesministerium für Bildung und Forschung (616891, 01GM1518C, STOP-FSGS-01GM1518C)
- Horizon 2020 Framework Programme (115974)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- mTOR signaling, mTORC1, focal segmental glomerulosclerosis, podocyte injury, raptors, rapamycin, oxidative phosphorylation, anaerobic glycolysis, reactive oxygen species, podocyte dedifferentiation
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Glomerulosclerosis, Focal Segmental, Humans, Immunosuppressive Agents, Signal Transduction, Disease Progression, Sirolimus, Multiprotein Complexes, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting mTOR Signaling Can Prevent the Progression of FSGS. https://app.cochat.ai/papers/10.1681/asn.2016050519
- The paper
- Zschiedrich, S., Bork, T., Liang, W., Wanner, N., Eulenbruch, K., Munder, S., Hartleben, B., Kretz, O., Gerber, S., Simons, M., Viau, A., Burtin, M., Wei, C., Reiser, J., Herbach, N., Rastaldi, M.-P., Cohen, C. D., Tharaux, P.-L., Terzi, F., . . . Huber, T. B. (2017). Targeting mTOR Signaling Can Prevent the Progression of FSGS. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2016050519
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.